Certara, Inc. (CERT)
Automate Your Wheel Strategy on CERT
With Tiblio's Option Bot, you can configure your own wheel strategy including CERT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CERT
- Rev/Share 2.4504
- Book/Share 6.7348
- PB 1.6868
- Debt/Equity 0.0118
- CurrentRatio 2.7774
- ROIC 0.0033
- MktCap 1842978240.0
- FreeCF/Share 0.5556
- PFCF 20.6025
- PE -696.7305
- Debt/Assets 0.0082
- DivYield 0
- ROE -0.0025
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CERT | Barclays | Equal Weight | Overweight | -- | $14 | May 8, 2025 |
| Initiation | CERT | TD Cowen | -- | Buy | -- | $16 | Feb. 27, 2025 |
| Upgrade | CERT | UBS | Neutral | Buy | -- | $16 | Sept. 27, 2024 |
News
3 Momentum Stocks That Could Soar Post-Market Volatility
Published: April 21, 2025 by: MarketBeat
Sentiment: Negative
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
Read More
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Published: April 14, 2025 by: Benzinga
Sentiment: Positive
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
Read More
Buy Certara After The FDA Announcement
Published: April 11, 2025 by: Seeking Alpha
Sentiment: Positive
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials.
Read More
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Published: April 11, 2025 by: Benzinga
Sentiment: Neutral
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Read More
Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferies Constantine Davides - Citizens Securities Andrew Moss - Bank of America Kyle Crews - UBS Operator Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2024 Earnings Conference Call.
Read More
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Certara, Inc. (CERT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
Read More
About Certara, Inc. (CERT)
- IPO Date 2020-12-11
- Website https://www.certara.com
- Industry Medical - Healthcare Information Services
- CEO Dr. William F. Feehery Ph.D.
- Employees 1487